NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025benzinga.comNovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
NovoCure Surpasses Q1 Expectationsfool.comNovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
NovoCure (NVCR) Q4 2024 Earnings Call Transcriptfool.comNVCR earnings call for the period ending December 31, 2024.
NovoCure Q4 EPS Misses, Revenue Matchesfool.comNovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025benzinga.comNovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'benzinga.comOn CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?benzinga.comThese 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?benzinga.comTop performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks.
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patientsbenzinga.comNovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients.
